JP2020516599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516599A5 JP2020516599A5 JP2019554725A JP2019554725A JP2020516599A5 JP 2020516599 A5 JP2020516599 A5 JP 2020516599A5 JP 2019554725 A JP2019554725 A JP 2019554725A JP 2019554725 A JP2019554725 A JP 2019554725A JP 2020516599 A5 JP2020516599 A5 JP 2020516599A5
- Authority
- JP
- Japan
- Prior art keywords
- dimethyl
- indazole
- amine
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 57
- 150000001875 compounds Chemical class 0.000 claims description 47
- -1 (3- (1,3-dimethyl-1H-indazole-5-yl) -2,5-dimethylpyrazolo [1,5-a] pyrimidin-7-yl) amino Chemical group 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 206010033645 Pancreatitis Diseases 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010010741 Conjunctivitis Diseases 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 5
- 208000003926 Myelitis Diseases 0.000 claims description 5
- 208000009525 Myocarditis Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010033799 Paralysis Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010040047 Sepsis Diseases 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 230000004900 autophagic degradation Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 206010014599 encephalitis Diseases 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 201000010901 lateral sclerosis Diseases 0.000 claims description 5
- 208000005264 motor neuron disease Diseases 0.000 claims description 5
- 208000030194 mouth disease Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 208000023504 respiratory system disease Diseases 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 4
- 206010035623 Pleuritic pain Diseases 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940127557 pharmaceutical product Drugs 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 208000005155 Picornaviridae Infections Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000013223 septicemia Diseases 0.000 claims description 3
- 206010040882 skin lesion Diseases 0.000 claims description 3
- 231100000444 skin lesion Toxicity 0.000 claims description 3
- WOFPLOFGYRLRJS-UHFFFAOYSA-N 3-(1,3-dimethylindazol-5-yl)-2,5-dimethyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CN1N=C(C)C2=C1C=CC(=C2)C1=C2N=C(C)C=C(NCC3=CC=NC=C3)N2N=C1C WOFPLOFGYRLRJS-UHFFFAOYSA-N 0.000 claims description 2
- YJJRTYKINMSQQF-UHFFFAOYSA-N 3-(1,3-dimethylindazol-5-yl)-2,5-dimethyl-N-(thiophen-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C=1C(=NC=2N(C=1NCC1=CC=CS1)N=C(C=2C1=CC=2C(=NN(C=2C=C1)C)C)C)C YJJRTYKINMSQQF-UHFFFAOYSA-N 0.000 claims description 2
- RZXUNLOIVLNMQA-UHFFFAOYSA-N 3-(1,3-dimethylindazol-5-yl)-2,5-dimethyl-N-[(4-methylsulfonylphenyl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CN1N=C(C)C2=C1C=CC(=C2)C1=C2N=C(C)C=C(NCC3=CC=C(C=C3)S(C)(=O)=O)N2N=C1C RZXUNLOIVLNMQA-UHFFFAOYSA-N 0.000 claims description 2
- YQTASBNNYQPVQL-UHFFFAOYSA-N 3-(1,3-dimethylindazol-5-yl)-2,5-dimethyl-N-[(6-methylpyridin-3-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CN1N=C(C)C2=C1C=CC(=C2)C1=C2N=C(C)C=C(NCC3=CC=C(C)N=C3)N2N=C1C YQTASBNNYQPVQL-UHFFFAOYSA-N 0.000 claims description 2
- KLHVRCVOQALCQV-UHFFFAOYSA-N 3-(1,3-dimethylindazol-5-yl)-2,5-dimethyl-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CN1N=C(C)C2=C1C=CC(=C2)C1=C2N=C(C)C=C(NCC3=CC=C(N=C3)C(F)(F)F)N2N=C1C KLHVRCVOQALCQV-UHFFFAOYSA-N 0.000 claims description 2
- ULOZTIYXFDFIFX-UHFFFAOYSA-N 3-(1,3-dimethylindazol-5-yl)-N-[(4-fluorophenyl)methyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound FC1=CC=C(CNC2=CC(=NC=3N2N=C(C=3C2=CC=3C(C)=NN(C=3C=C2)C)C)C)C=C1 ULOZTIYXFDFIFX-UHFFFAOYSA-N 0.000 claims description 2
- JITYVOBUUFSWAW-UHFFFAOYSA-N 3-(1,3-dimethylindazol-5-yl)-N-[(4-methoxyphenyl)methyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound COC1=CC=C(CNC2=CC(C)=NC3=C(C(C)=NN23)C2=CC3=C(C=C2)N(C)N=C3C)C=C1 JITYVOBUUFSWAW-UHFFFAOYSA-N 0.000 claims description 2
- QGVAIRIHEYEWJS-UHFFFAOYSA-N 3-(1,3-dimethylindazol-5-yl)-N-[(6-methoxypyridin-3-yl)methyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CN1N=C(C2=CC(=CC=C12)C=1C(=NN2C=1N=C(C=C2NCC=1C=NC(=CC=1)OC)C)C)C QGVAIRIHEYEWJS-UHFFFAOYSA-N 0.000 claims description 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- KBRKERCJKFMZEM-UHFFFAOYSA-N 8-(1,3-dimethylindazol-5-yl)-2,7-dimethyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N1=CC=C(C=C1)CNC1=NC(=NC=2N1N=C(C=2C1=CC=2C(=NN(C=2C=C1)C)C)C)C KBRKERCJKFMZEM-UHFFFAOYSA-N 0.000 claims description 2
- SIENVEHBXCWECI-UHFFFAOYSA-N 8-(1,3-dimethylindazol-5-yl)-2,7-dimethyl-N-(thiophen-2-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(=NC=2N(C=1NCC1=CC=CS1)N=C(C=2C1=CC=2C(=NN(C=2C=C1)C)C)C)C SIENVEHBXCWECI-UHFFFAOYSA-N 0.000 claims description 2
- NBLBPINRSZKXJF-UHFFFAOYSA-N 8-(1,3-dimethylindazol-5-yl)-2,7-dimethyl-N-[(4-methylsulfonylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound S(=O)(=O)(C1=CC=C(CNC2=NC(=NC=3N2N=C(C=3C2=CC=3C(=NN(C=3C=C2)C)C)C)C)C=C1)C NBLBPINRSZKXJF-UHFFFAOYSA-N 0.000 claims description 2
- QXKBMTCFPXKHDN-UHFFFAOYSA-N 8-(1,3-dimethylindazol-5-yl)-2,7-dimethyl-N-[(6-methylpyridin-3-yl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound Cc1nn2c(NCc3ccc(C)nc3)nc(C)nc2c1-c1ccc2n(C)nc(C)c2c1 QXKBMTCFPXKHDN-UHFFFAOYSA-N 0.000 claims description 2
- KPWFAUMDCXWFEX-UHFFFAOYSA-N 8-(1,3-dimethylindazol-5-yl)-N-[(4-methoxyphenyl)methyl]-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound COC1=CC=C(CNC2=NC(C)=NC3=C(C(C)=NN23)C2=CC3=C(C=C2)N(C)N=C3C)C=C1 KPWFAUMDCXWFEX-UHFFFAOYSA-N 0.000 claims description 2
- YEKJZRWQOMWPMI-UHFFFAOYSA-N 8-(1,3-dimethylindazol-5-yl)-N-[(6-methoxypyridin-3-yl)methyl]-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound COc1ccc(CNc2nc(C)nc3c(c(C)nn23)-c2ccc3n(C)nc(C)c3c2)cn1 YEKJZRWQOMWPMI-UHFFFAOYSA-N 0.000 claims description 2
- INIHKJIARHRCAP-UHFFFAOYSA-N N-[(4-chlorophenyl)methyl]-3-(1,3-dimethylindazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound ClC1=CC=C(CNC=2N3C(N=C(C=2)C)=C(C2=CC4=C(C=C2)N(N=C4C)C)C(=N3)C)C=C1 INIHKJIARHRCAP-UHFFFAOYSA-N 0.000 claims description 2
- ICIHYCCESPOYJG-UHFFFAOYSA-N N-[(4-chlorophenyl)methyl]-8-(1,3-dimethylindazol-5-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound CN1N=C(C)C2=C1C=CC(=C2)C1=C2N=C(C)N=C(NCC3=CC=C(Cl)C=C3)N2N=C1C ICIHYCCESPOYJG-UHFFFAOYSA-N 0.000 claims description 2
- UQYGFIRDOHPVOD-UHFFFAOYSA-N N-[4-[[[3-(1,3-dimethylindazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]phenyl]methanesulfonamide Chemical compound CN1N=C(C)C2=C1C=CC(=C2)C1=C2N=C(C)C=C(NCC3=CC=C(NS(C)(=O)=O)C=C3)N2N=C1C UQYGFIRDOHPVOD-UHFFFAOYSA-N 0.000 claims description 2
- DZORMANSUVIHFZ-UHFFFAOYSA-N N-benzyl-3-(1,3-dimethylindazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=CC=C(C=C1)CNC1=CC(=NC=2N1N=C(C=2C1=CC=2C(C)=NN(C=2C=C1)C)C)C DZORMANSUVIHFZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 210000003020 exocrine pancreas Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 241000709675 Coxsackievirus B3 Species 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17165082.3 | 2017-04-05 | ||
| EP17165082 | 2017-04-05 | ||
| PCT/EP2018/058522 WO2018185120A1 (en) | 2017-04-05 | 2018-04-04 | Heteroaromatic compounds useful in therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516599A JP2020516599A (ja) | 2020-06-11 |
| JP2020516599A5 true JP2020516599A5 (https=) | 2021-05-13 |
| JP7200126B2 JP7200126B2 (ja) | 2023-01-06 |
Family
ID=58489645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554725A Active JP7200126B2 (ja) | 2017-04-05 | 2018-04-04 | 療法において有用なヘテロ芳香族化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11001587B2 (https=) |
| EP (1) | EP3606926B1 (https=) |
| JP (1) | JP7200126B2 (https=) |
| CN (1) | CN110520424B (https=) |
| AU (1) | AU2018248581B2 (https=) |
| CA (1) | CA3057408A1 (https=) |
| DK (1) | DK3606926T3 (https=) |
| ES (1) | ES2880327T3 (https=) |
| NZ (1) | NZ758449A (https=) |
| PL (1) | PL3606926T3 (https=) |
| RU (1) | RU2770363C2 (https=) |
| WO (1) | WO2018185120A1 (https=) |
| ZA (1) | ZA201907303B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017147526A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| DK3606926T3 (da) * | 2017-04-05 | 2021-07-05 | Curovir Ab | Heteroaromatiske forbindelser anvendelige i terapi |
| WO2020074160A1 (en) | 2018-10-10 | 2020-04-16 | Curovir Ab | Condensed pyrimidine or pyridazine derivatives as antiviral agents |
| CA3115128A1 (en) | 2018-10-10 | 2020-04-16 | Curovir Ab | 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections |
| CA3126143A1 (en) * | 2019-01-11 | 2020-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | Pi4-kinase inhibitors with anti-cancer activity |
| KR20220035322A (ko) | 2019-03-21 | 2022-03-22 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Pi4-키나아제 억제제 및 이의 사용 방법 |
| EP4028131B1 (en) | 2019-08-20 | 2023-11-22 | Curovir Ab | Heteroaromatic compounds useful in therapy |
| EP4676485A1 (en) | 2023-03-09 | 2026-01-14 | Curovir Ab | Compound and formulation for systemic therapy by oral transmucosal administration |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
| US6191131B1 (en) * | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| JP2003510325A (ja) * | 1999-09-30 | 2003-03-18 | ニューロジェン・コーポレーション | ある種のアルキレンジアミン−置換ピラゾロ［１，５−ａ］−１，５−ピリミジン及びピラゾロ［１，５−ａ］−１，３，５−トリアジン |
| RU2340611C2 (ru) * | 2000-09-15 | 2008-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, используемые в качестве ингибиторов протеинкиназы |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| FR2943058B1 (fr) | 2009-03-11 | 2011-06-03 | Centre Nat Rech Scient | Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique. |
| HRP20190128T1 (hr) * | 2011-05-04 | 2019-03-08 | Rhizen Pharmaceuticals S.A. | Novi spojevi kao modulatori protein kinaza |
| EP2634189A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors |
| RU2689788C2 (ru) * | 2014-01-22 | 2019-05-29 | Куровир Аб | ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ |
| WO2015140491A1 (en) * | 2014-03-18 | 2015-09-24 | Micromass Uk Limited | Liquid extraction matrix assisted laser desorption ionisation ion source |
| CN107949563B (zh) | 2015-06-24 | 2020-06-05 | 库洛维公司 | 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物 |
| DK3606926T3 (da) * | 2017-04-05 | 2021-07-05 | Curovir Ab | Heteroaromatiske forbindelser anvendelige i terapi |
-
2018
- 2018-04-04 DK DK18716212.8T patent/DK3606926T3/da active
- 2018-04-04 ES ES18716212T patent/ES2880327T3/es active Active
- 2018-04-04 WO PCT/EP2018/058522 patent/WO2018185120A1/en not_active Ceased
- 2018-04-04 AU AU2018248581A patent/AU2018248581B2/en active Active
- 2018-04-04 US US16/495,903 patent/US11001587B2/en active Active
- 2018-04-04 RU RU2019133777A patent/RU2770363C2/ru not_active Application Discontinuation
- 2018-04-04 NZ NZ758449A patent/NZ758449A/en unknown
- 2018-04-04 EP EP18716212.8A patent/EP3606926B1/en active Active
- 2018-04-04 JP JP2019554725A patent/JP7200126B2/ja active Active
- 2018-04-04 PL PL18716212T patent/PL3606926T3/pl unknown
- 2018-04-04 CA CA3057408A patent/CA3057408A1/en active Pending
- 2018-04-04 CN CN201880023679.2A patent/CN110520424B/zh active Active
-
2019
- 2019-11-04 ZA ZA2019/07303A patent/ZA201907303B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516599A5 (https=) | ||
| US8921381B2 (en) | Inhibitors of secretion of hepatitis B virus antigens | |
| CN101443330B (zh) | 杂环非核苷类化合物及其制备方法、药物组合物和作为抗病毒抑制剂的用途 | |
| JP2016517857A5 (https=) | ||
| JP2016533379A5 (https=) | ||
| CN109476663A (zh) | 用于治疗癌症的吡唑并吡啶衍生物 | |
| WO2015120178A1 (en) | Combination therapy for treatment of hbv infections | |
| KR102634247B1 (ko) | 다발성 골수종을 치료하기 위한 약물 병용물 | |
| JP2022078996A (ja) | 重篤なインフルエンザの治療又は予防のための方法及び化合物 | |
| JP2019511542A (ja) | カプシド集合阻害剤を含む組み合わせ及び方法 | |
| JP2018536681A (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| WO2014145642A9 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
| BR112020018094A2 (pt) | Compostos de aminopirazina diol como inibidores de pi3k-¿ | |
| RU2019133777A (ru) | Гетероароматические соединения, пригодные в терапии | |
| JP2016525104A5 (https=) | ||
| JP2018522861A5 (https=) | ||
| JP2017503830A5 (https=) | ||
| JP2025529629A (ja) | 腫瘍の処置における放射線治療と組み合わせたイミダゾリノン誘導体の使用 | |
| US9469625B2 (en) | Organic compounds | |
| CN1638772A (zh) | 抗病毒化合物 | |
| KR102399732B1 (ko) | 2-[3-[4-(1h-인다졸-5-일아미노)퀴나졸린-2-일]페녹시]-n-아이소프로필아세트아마이드를 유효성분으로 함유하는 코로나-19의 예방 또는 치료용 약학적 조성물 | |
| WO2014123680A1 (en) | Antimicrobial methods using inhibitors of exchange proteins directly activated by camp (epac) | |
| JP7768770B2 (ja) | Ｐｄｌ１チェックポイント阻害剤としての複素環式免疫調節剤 | |
| TWI920088B (zh) | Ｓｉｋ-３抑制劑及其用途 | |
| CN111632146B (zh) | Oat抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |